Disease Team Research I

Return to Grants

RFA 09-01:CIRM Disease Team Research Awards

The CIRM Disease Team Research Awards will fund actively managed multidisciplinary teams engaged in milestone-driven translational research for the development of stem cell-based therapies. The mission of these teams will be to conduct the necessary research and regulatory activities to prepare and file a complete, well supported Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) (and, if desired, other regulatory agencies), to enable Phase I clinical testing. The Disease Team Research Award is core to CIRM’s mission and as such, the agency will likely solicit applications every twelve to eighteen months as a way to build a strong clinical pipeline for patient therapies and cures. This RFA includes CIRM’s Collaborative Funding Partner Program, and the CIRM Loan Program.

Please see the RFA for full details.

Section III Award Information has been amended to clarify that $3 million to $20 million per project is the range for total funds requested (includes direct project costs, direct facilities costs, and indirect costs)

  • For more information on the CIRM Loan Program see the Loan FAQ.

Preliminary Application Instructions and Forms

Submission of an application for the CIRM Disease Team Research Award involves a two step process in which an applicant first submits a Preliminary Application (Pre-Application; PreApp) and subsequently submits a full application only if invited to do so by CIRM.  PreApps will be evaluated by scientific specialists from outside California who are experts in specific areas of research described in the PreApp and by CIRM scientific staff, based on scientific review criteria described in section VII of the RFA.  Applicants whose projects are judged as most promising, competitive, and responsive to the RFA will be invited to submit a full application.  Applicants who are not invited to submit a full application will be deferred.

Each applicant must submit a Pre-Application using the PreApp Form. In addition to the PreApp form, applicants must submit a Related Business Entities Disclosure Form. Each investigator may submit one preliminary application (PreApp, See Section VI) as either a PI or a Co-PI; and, the same investigator may be a Co-PI on up to one additional preliminary application. An investigator who applied as a PI on CIRM RFA 08-05 “Early Translational Research Award” is not eligible to apply as a PI, but may apply as a Co-PI on this award.

The completed PreApp form (less the Official signature) and the Related Business Entities Disclosure Form must be sent as interactive pdf documents (the original document format; documents must not be “flattened” or converted to another format) as email attachments to DiseaseTeamPreApp@CIRM.ca.gov and must be received by CIRM no later than 5:00 pm (PDT) on March 26, 2009.  Additionally, a hard copy of the cover (first) page of the PreApp, signed by an institutional official authorized to sign on behalf of the applicant’s organization, must be received by CIRM no later than 5:00 pm (PDT), on March 26, 2009.

Applicants whose proposals include a CIRM/Funding Partner team must also send an electronic copy of this PreApp to the designated partner point-of-contact email listed in the Appendices of the RFA.

The signed cover page must be sent to:

Disease Team Research Award PreApp
California Institute for Regenerative Medicine
210 King Street
San Francisco, CA 94107

It is the applicant’s responsibility to meet this deadline; no exceptions will be made.

You will need a fully functional copy of Adobe Acrobat version 7 or 8 (Standard or Professional) to complete, print, and save the PreApp, Related Business Entities Disclosure Forms.  We recommend using Adobe Acrobat version 8.1 (or the latest version). Using Adobe Acrobat Reader will not permit you to save information that is entered in the form.

Full Application Instructions and Forms

Full Applications will only be accepted from applicants who 1) submitted a PreApp and 2) are invited by CIRM to submit a Full Application.

The full application for the Disease Team Research Award consists of five parts:  Part A: Application Information Form, Part B: Disease Team Award Research Proposal, Part C: Biographical Sketches for Key Personnel, Part D: Institutional Letter(s) of Commitment, and Part E: Related Business Entities Disclosure Form.

All five parts of the full application for CIRM Disease Team Research Awards must be submitted together and received by CIRM no later than 5:00 pm (PDT) on July 16, 2009, in both electronic form and in hard copy (a signed original and five copies). It is the applicant’s responsibility to meet this deadline; no exceptions for late applications will be made.

Send electronic copies of all parts of the application as attachments in a single email to DiseaseTeamResearchAwards@cirm.ca.gov. Applicants whose proposals include a CIRM/Funding Partner team must also send an electronic copy of the full application (Parts A-E) to the designated partner point-of-contact email listed in the Appendices of the RFA.

In addition to the electronic submission, candidates must submit an original copy of the application (consisting of Parts A-E) plus 5 copies of the full application (preferably double-sided) to the mailing address below. The original copy must be signed by both the PI and the applicant institution’s Authorized Organizational Official (AOO). Applications designating a Co-PI(s) must also be signed by the Co-PI and the Co-PI’s institutional AOO.

Disease Team Research Awards Application
California Institute for Regenerative Medicine
210 King Street
San Francisco, CA 94107

You will need a fully functional copy of Adobe Acrobat version 7 or 8 (Standard or Professional) to complete, print, and save Parts A and E of the Full Application.  We recommend using Adobe Acrobat version 8.1 (or the latest version). Using Adobe Acrobat Reader will not permit you to save information that is entered in the form.

Schedule of Deadlines and Reviews

Schedule of Deadlines and Reviews Date
Pre-Applications for Disease Team Research Awards due 5:00 PM (PDT), March 26, 2009
Invitations for full applications sent out by CIRM Mid May 2009
Full applications due 5:00 PM (PDT), July 16, 2009
Review of full applications by Grants Working Group (GWG) September 2009
Review and Approval by ICOC Fall 2009
Earliest Funding of Awards December 2009

No exceptions will be made to the indicated deadlines.

Schedule of additional collaborative funding partner deadlines

For full details of Collaborative Funding Partner submission requirements, consult the Appendices B-D of the RFA.

Cancer Stem Cell Consortium, Canada – Schedule of Additional Deadlines Date
Notification of Intent to Submit a Pre-application February 25, 2009
Electronic copy of Pre-application due March 26, 2009
CSCC Budget Form due June 25, 2009
Electronic copy of full application due July 16, 2009
 
Spanish Ministry of Science and Innovation – Schedule of Additional Deadlines Date
Electronic copy of Pre-application due March 26, 2009
Curriculum vitae March 26, 2009
Preliminary overview of Spanish project budget March 26, 2009
Electronic copy of full application due July 16, 2009
Detailed justification funding requested from MICINN July 16, 2009
 
Medical Research Council – Schedule of Additional Deadlines Date
Electronic copy of Pre-application due March 26, 2009
Electronic copy of full application due July 16, 2009

 


ICOC Approval:
October 28, 2009
Total Awards:
15
Award Value:
$182,842,804

Awards

Institution Investigator Grant Title Award Value
Calimmune, Inc. Geoff Symonds GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE $8,278,722
Stanford University Dr. Gary Steinberg Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke $17,244,851
University of California, San Diego Dr. Lawrence S. B. Goldstein Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis $5,694,308
University of California, Los Angeles Dr. Donald B. Kohn Stem Cell Gene Therapy for Sickle Cell Disease $8,833,695
University of California, Los Angeles Dr. Irvin SY Chen HPSC based therapy for HIV disease using RNAi to CCR5. $9,905,604
ViaCyte, Inc. Allan Robins Cell Therapy for Diabetes $0
Cedars-Sinai Medical Center Eduardo Marbán Autologous cardiac-derived cells for advanced ischemic cardiomyopathy $5,560,232
University of California, San Francisco Dr. Mitchel S Berger Stem Cell-Mediated Oncocidal Gene Therapy of Glioblastoma (GBM) $6,214,914
City of Hope, Beckman Research Institute Prof. Karen S Aboody M.D. Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials $17,890,623
Stanford University Dr. Alfred T Lane iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa $11,039,208
Stanford University Dr. Irving L Weissman MD Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells $18,759,276
University of California, Los Angeles Dr. Dennis J Slamon Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors $19,979,660
City of Hope, Beckman Research Institute Prof. John A Zaia ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS $14,536,969
University of Southern California Dr. Mark S Humayun Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916
University of California, San Diego Dr. Dennis A Carson Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) $19,999,826
Total:
$182,842,803.66